8-K: TriSalus Life Sciences Launches Exchange Offer and Consent Solicitation to Streamline Capital Structure

TriSalus Life Sciences, Inc. has commenced an exchange offer and consent solicitation for its Series A Convertible Preferred Stock to simplify its capital structure and reduce potential dilution.

Summary

• TriSalus Life Sciences, Inc. (TLSI) has initiated an exchange offer for its Series A Convertible Preferred Stock, allowing holders to exchange each share for Common Stock based on its accrued value (including dividends through August 10, 2027) divided by $4.00.
• The company is offering up to an aggregate of 11,860,206 shares of its Common Stock in this exchange.
• Concurrently, TriSalus is soliciting consents from preferred shareholders to amend the Certificate of Designations, which, if approved, would permit the company to mandatorily convert all remaining Preferred Stock into Common Stock after the offer closes.
• The mandatory conversion ratio for non-tendering preferred shares would be 11.3% less favorable than the exchange ratio offered in the voluntary exchange.
• Parties representing approximately 55% of the outstanding Preferred Stock have already agreed to tender their shares and consent to the proposed amendment.
• The offer and consent solicitation are set to expire at 12:01 a.m. Eastern Time on July 23, 2025, unless extended.
• As of June 13, 2025, there were 3,594,002 shares of Preferred Stock outstanding.
• The company filed a registration statement on Form S-4 and an exchange offer statement on Schedule TO with the SEC on June 23, 2025, detailing the offer.

Sentiment

Score: 7

Explanation: The announcement is generally positive for common shareholders as it aims to simplify the capital structure, reduce potential future dilution, and improve transparency. The strong pre-commitment from preferred shareholders indicates a high likelihood of success. The less favorable conversion terms for non-tendering preferred shareholders are a strategic incentive for participation, not a broad negative for the company's overall health.

Positives

• The initiative aims to simplify TriSalus's capital structure, eliminating complex layers and potential preferential claims.
• It is expected to reduce the potential dilutive impact from the Preferred Stock on common shareholders.
• The simplification provides investors with a clearer view of the company's equity value and improves transparency around ownership.
• Significant support has already been secured, with approximately 55% of outstanding Preferred Stock holders agreeing to tender their shares and consent to the amendment, increasing the likelihood of successful completion.

Negatives

• Preferred shareholders who do not tender their shares in the exchange offer may face a mandatory conversion into Common Stock at a ratio that is 11.3% less favorable than the exchange ratio offered in the voluntary exchange.

Risks

• The Company's ability to successfully complete the Offer and Consent Solicitation.
• The number of holders of shares of Preferred Stock that approve the Preferred Stock Amendment in the Consent Solicitation.
• The timing and results of the SEC review of the registration statement on Form S-4 filed on June 23, 2025.
• The Company's ability to attract and retain customers and expand customers' use of the Company's products.
• Risks relating to market, financial, political and legal conditions.
• Risks relating to the uncertainty of the projected financial and operating information with respect to the Company.
• Risks related to future market adoption of the Company's offerings.
• Risks related to the Company's marketing and growth strategies.
• Risks related to the Company's ability to acquire or invest in businesses, products or technologies that may complement or expand its products, enhance its technical capabilities or otherwise offer growth opportunities.
• The effects of competition on the Company's future business.
• General risks discussed in the Company's quarterly report on Form 10-Q for the period ended March 31, 2025, under the heading Risk Factors.
• General risks discussed in the Company's Registration Statement on Form S-4 filed on June 23, 2025, under the heading Risk Factors and other documents of the Company filed, or to be filed, with the SEC.

Future Outlook

TriSalus Life Sciences anticipates that the successful completion of the exchange offer and consent solicitation will simplify its capital structure, reduce potential future dilution from Preferred Stock, and enhance transparency for investors. The company expects the Preferred Stock Amendment to be adopted given the existing support agreements from a significant portion of preferred shareholders.

Management Comments

• "TriSalus is committed to simplifying its capital structure and reducing the potential impact of dilution from its Preferred Stock."
• "By exchanging outstanding shares of Preferred Stock for common stock, the Company eliminates complex capital layers and potential preferential claims, providing investors with a clearer view of the Company's equity value and improving transparency around ownership."

Industry Context

This capital structure simplification initiative by TriSalus Life Sciences aligns with a common trend in the biotech and medical technology sectors, where companies often seek to streamline their equity structures to improve investor appeal and reduce financial complexities. By converting preferred shares to common stock, TriSalus aims to present a cleaner balance sheet and a more straightforward equity story, which can be particularly attractive to a broader base of institutional and retail investors looking for clarity and reduced overhangs in growth-stage companies.

Comparison to Industry Standards

• The act of simplifying a complex capital structure, particularly by converting preferred stock to common stock, is a standard corporate finance practice across various industries, including biotech and medtech.
• The pre-commitment from approximately 55% of preferred shareholders to tender their shares and consent to the amendment is a strong indicator of the likely success of such an offer, often sought by companies to de-risk the transaction and ensure sufficient participation for the desired outcome.

Corporate Governance

Stakeholder Impact

• **Common Shareholders**: Expected to benefit from a simplified capital structure, reduced potential dilution, and improved transparency regarding the company's equity value.
• **Preferred Shareholders**: Those who tender their shares will convert to common stock at the offered ratio. Those who do not tender may face mandatory conversion at a less favorable ratio (11.3% less) if the amendment is approved, incentivizing participation.
• **Investors**: Will gain a clearer and more transparent view of the company's equity value and ownership structure, potentially making the stock more attractive.

Next Steps

• The Offer and Consent Solicitation will expire at 12:01 a.m. Eastern Time on July 23, 2025, unless extended.
• The SEC will review the registration statement on Form S-4 filed on June 23, 2025.
• If the Preferred Stock Amendment is approved and the offer closes, remaining outstanding Preferred Stock may be mandatorily converted into Common Stock.

Key Dates

Recommendation

Keywords

TriSalus Life Sciences, TLSI, Exchange Offer, Consent Solicitation, Preferred Stock, Common Stock, Capital Structure, Dilution, SEC Filing, 8-K, Corporate Governance, Nasdaq, Medical Technology, Oncology, Drug Delivery, Immunotherapy